UK PrEP programme could prevent up to one in four cases of HIV
Wednesday 18 October 2017
Our Medical Director responds to a new study on PrEP.
The Lancet Infectious Diseases has today published a study into the HIV prevention tool, PrEP, titled, 'UK-wide PrEP programme would be cost-effective, and could prevent up to one in four cases of HIV'.
Dr Michael Brady, Medical Director at Terrence Higgins Trust, said: “One of the key arguments against PrEP has been that it will cost the NHS too much money. This study firmly puts that claim to bed by demonstrating that, when appropriately targeted at those at risk of HIV, it is not only highly cost effective but, as the price of HIV drugs falls, will actually save the NHS money in the long run. Each HIV infection prevented saves the NHS £360,000 of a lifetime of treatment and care.
“The study also highlights the importance of cheaper, generic versions of PrEP, which are currently being used in NHS England’s PrEP Impact trial and have been commissioned for PrEP use in Scotland.
“This cost effectiveness data underlines the importance of PrEP in the fight against HIV. It is not only highly clinically effective, it is also cost effective. The NHS England Impact trial, which will provide access to PrEP for 10,000 people over the next three years, is a welcome step in the right direction. However, it is important that all who need PrEP can access it and evidence like this reinforces the need for PrEP to be fully commissioned and given a long-term, sustainable home on the NHS in England."